ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÕÅæÃæÃ¡¢¡¢´÷Ï£°²¡¢¡¢¼òÎÄÑ¹ØÓÚ¾Ö²¿ÍíÆÚµÄÖ±³¦°©£¬ÏÖÔÚÖ÷Òª½ÓÄÉи¨ÖúÖÎÁƽµµÍÖ×Áö·ÖÆÚÒÔ¸ÄÉÆÖÎÁÆÐ§¹û£¬¿ÉÊÇÓÐÏ൱һ²¿·ÖµÄ»¼Õß¶Ôи¨Öú»¯ÁÆÄÍÒ©£¬Ô¤ºó¼«²î¡£Òò´Ë£¬ÉîÈë̽Ë÷Ö±³¦°©¶Ôи¨Öú»¯ÁÆÄÍÒ©µÄ·Ö×Ó»úÖÆ£¬ÓÐÀûÓÚ·¢Ã÷еÄÖÎÁưе㣬¿ª·¢ÐµÄÖÎÁÆ·½°¸¡£¿ËÈÕ£¬Á¥ÊôµÚÁùÒ½ÔºÎâС½£¡£¡¢¡¢ÓàÕÕÁÁ¿ÎÌâ×éÓëÁ¥ÊôÖ×ÁöҽԺ̷¾²¿ÎÌâ×éÔÚÃÀ¹ú¹ú¼Ò¿ÆÑ§ÔºÔº¿¯PNASÉϽÒÏþÁËÌâΪPharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancerµÄÑо¿ÂÛÎÄ¡£Ñо¿ÍŶÓͨ¹ýÃè»æÐ¸¨Öú»¯ÁÆÄÍÒ©ÐÍÖ±³¦°©µÄÖ×Áö·Ö×ÓÌØÕ÷, Á¬Ïµ¸ßͨÁ¿Ò©É¸É¸Ñ¡£¬·¢Ã÷CDK4/6ÒÖÖÆ¼Á¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬ÁÆÐ§£¬½øÒ»²½Ê¹Óöà×éѧ²âÐòÊÖÒÕ£¨È«×ªÂ¼×é²âÐòºÍ±í¹ÛÒÅ´«×é²âÐòµÈ£©Õ¹ÏÖÁ˵±ÖеķÖ×Ó»úÖÆ£¬ÎªÐ¸¨Öú»¯ÁÆÄÍÒ©µÄÖ±³¦°©»¼ÕßÌṩÁËеÄÖÎÁÆË¼Ð÷¡£
и¨Öú»¯ÁÆÊÇÏÖÔÚÁÙ´²ÉÏÖÎÁƾֲ¿ÍíÆÚÖ±³¦°©µÄÖ÷ÒªÊֶΣ¬¿ÉÊÇÔ¼30%-60%µÄÖ±³¦°©»¼Õß¶ÔÏÖÔÚи¨Öú»¯ÁÆ·½°¸²»Ãô¸Ð£¬Ö×ÁöÍËËõ½ÏС»òÕßÉõÖÁ²»ÍËËõ£¬È»¶øÁÙ´²ÉÏÓÖȱ·¦¸ü¶àµÄÒ©ÎïÖÎÁÆÑ¡Ôñ£¬ÕâȺ»¼ÕßµÄÊõºó¸¨ÖúÖÎÁƶàÊǼÌÐøÑØÓÃÒ»ÏߵϝÁÆ·½°¸£¬Ô¤ºó¼«²î¡£ÎªÁË̽Ë÷³¦°©Ð¸¨Öú»¯ÁÆÄÍÒ©µÄÖ×Áö·Ö×ÓÌØÕ÷£¬Ñо¿ÍŶÓÊ×ÏÈÍøÂçÁËÈ´Ö±³¦°©Ö×Áö×éÖ¯¾ÙÐÐת¼×é²âÐò£¬ÔÙ¸ú×ÙËæ·Ã²¡ÈË»¯ÁÆÐ§¹û£¬Æ¾Ö¤ÁÆÐ§°Ñ²¡ÈË·ÖΪ»¯ÁÆÃô¸ÐÐͺÍÄÍÒ©ÐÍ£¬¾ÙÐзÖ×éÆÊÎö¡£Ð§¹û·¢Ã÷ÄÍÒ©ÐÍÖ×Áö×éÖ¯ÖÐϸ°ûÖÜÆÚÏà¹ØµÄÐźÅÒì³£»£»î»¯£¬ÌáÐÑÒÔ¡°°ÐÏòÒì³£µÄϸ°ûÖÜÆÚ¼ì²éµã¡±Ñ°ÕÒÖÎÁưеã¿ÉÄÜ¿ÉÒÔÄæ×ª»¯ÁÆÄÍÒ©¡£ÓÚÊǽøÒ»²½Ê¹ÓÃС·Ö×ÓÒÖÖÆ¼ÁÎÄ¿â¾ÙÐиßͨÁ¿É¸Ñ¡£¬·¢Ã÷CDK4/6ÒÖÖÆ¼Á¿ÉÒÔÓÐÓÃÌá¸ß°ÂɳÀû²¬Ãô¸ÐÐÔ£¬²¢ÇÒ¿ÉÒÔÐͬÒÖÖÆÖ×Áöϸ°ûÔöÖ³¡£»£»úÖÆÉÏ£¬Í¨¹ýÕûºÏȫת¼×é²âÐòÆÊÎöºÍȾɫÖʹ²³Áµí²âÐòÆÊÎö·¢Ã÷CDK4/6ÒÖÖÆ¼Áͨ¹ýÓ°Ïì±í¹ÛÒÅ´«ÐÞÊε÷¿ØÍ¬Ô´ÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬´Ó¶øÚ¹ÊÍÁËCDK4/6ÒÖÖÆ¼ÁΪºÎ¿ÉÒÔÄæ×ª°ÂɳÀû²¬ÄÍÒ©Õ÷ÏóµÄ»úÖÆ£¬¸ÃÑо¿ÓÐÍûΪи¨Öú»¯ÁÆÄÍÒ©µÄÖ±³¦°©»¼ÕßÌṩеÄÓÃÒ©Ñ¡Ôñ£¨Í¼1£©¡£

ͼ1 CDK4/6ÒÖÖÆ¼Áͨ¹ýÓ°Ïì±í¹ÛÒÅ´«ÐÞÊε÷¿ØÍ¬Ô´ÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬´Ó¶øÄæ×ª°ÂɳÀû²¬ÄÍÒ©Õ÷Ïó
Ñо¿ÍŶÓͨ¹ýÍøÂç34Àýи¨ÖúÖÎÁÆÇ°µÄ¾Ö²¿Ï£ÍûÆÚÖ±³¦°©»¼ÕßÖ×ÁöÑù±¾£¬Æ¾Ö¤Ð¸¨ÖúÖÎÁƺóÊÖÊõÇгýµÄÖ×ÁöÑù±¾²¡ÀíÇÐÆ¬¾ÙÐÐÖ×ÁöÍËËõÆÀ¼Û£¨Tumor regression grade£¬TRG£©£¬¶Ô²¡È˾ÙÐзÖÀ࣬²¢ÆÊÎöÄÍÒ©Ïà¹ØµÄÖ×Áö·Ö×ÓÌØÕ÷£¨Í¼2£©¡£

ͼ2 и¨Öú»¯ÁÆÄÍÒ©Ïà¹ØµÄÖ×Áö·Ö×ÓÌØÕ÷
ΪÁËѰÕÒÖÎÁưе㣬Ñо¿ÍŶÓʹÓÃС·Ö×ÓÒÖÖÆ¼ÁÎÄ¿â¾ÙÐиßͨÁ¿Ò©Îïɸѡ£¬·¢Ã÷CDK4/6ÒÖÖÆ¼Á¿ÉÒÔÏÔÖøÌá¸ß°ÂɳÀû²¬Ò©Ð§£¨Í¼3£©¡£

ͼ3 С·Ö×ÓÒÖÖÆ¼ÁÎÄ¿âÒ©Îïɸѡ·¢Ã÷CDK4/6ÒÖÖÆ¼Á¿ÉÏÔÖøÌá¸ß°ÂɳÀû²¬Ò©Ð§
×îºó£¬Í¨¹ýÕûºÏÆÊÎöRNA-seqºÍChIP-seqÊý¾Ý£¬CDK4/6ÒÖÖÆ¼Áͨ¹ý±í¹ÛÒÅ´«ÐÞÊε÷¿ØRB1-TEAD4ÐźÅÖáÓ°ÏìÍ¬Ô´ÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï£¬´Ó¶øÄæ×ª°ÂɳÀû²¬ÄÍÒ©Õ÷Ïó£¨Í¼4£©¡£

ͼ4 CDK4/6ÒÖÖÆ¼Áͨ¹ý±í¹ÛÒÅ´«ÐÞÊε÷¿ØÍ¬Ô´ÖØ×éÐÞ¸´Ïà¹Ø»ùÒòµÄ±í´ï
ÖµµÃÒ»ÌáµÄÊÇ£¬»ùÓڸûù´¡Ñо¿Ð§¹û£¬ÒѽøÒ»²½¿ªÕ¹ÁÙ´²ÊÔÑ飨CDK4/6ÒÖÖÆ¼ÁÁªºÏ»¯ÁÆÓÃÓÚÍíÆÚ/×ªÒÆÐÔ½áÖ±³¦°©µÄÁÙ´²×ª»¯Ñо¿£¬Clinical Trial£ºNCT05480280£©£¬ÏÖÔÚ¶àÀý¾±ê×¼ÖÎÁÆÊ§°ÜµÄÍíÆÚ³¦°©²¡ÈËÒÑÈë×飬²¢ÒÑÊӲ쵽²¿·ÖÈë×黼ÕßÁÙ´²»ñÒæ£¬ÆäÓÐÍûÌá¸ßи¨Öú»¯ÁÆÄÍÒ©µÄ²¡ÈËÔ¶ÆÚÁÆÐ§¡£
Á¥ÊôµÚÁùÒ½ÔºÎâС½£½ÌÊÚºÍÁ¥ÊôÖ×ÁöҽԺ̷¾²Ñо¿Ô±Îª±¾ÂÛÎĵÄͨѶ×÷Õߣ¬ÓàÕÕÁÁҽʦ¡¢¡¢µËÅô²©Ê¿ÒÔ¼°³Âîڷ渱Ö÷ÈÎҽʦΪ±¾ÎĵÄÅäºÏµÚÒ»×÷Õߣ¬±¾Ñо¿»¹»ñµÃÁËÐÂ¼ÓÆÂ»ùÒò×éÑо¿ÔºÓÚÇ¿½ÌÊÚ¡¢¡¢ÐÂ¼ÓÆÂ¹úÁ¢°©Ö¢ÖÐÐÄBin Tean Teh½ÌÊÚºÍÁ¥ÊôµÚÁùÒ½ÔºÍõÎÄÓÑо¿Ô±µÄ´óÁ¦Ö§³Ö¡£
ÂÛÎÄÁ´½Ó£ºhttps://doi.org/10.1073/pnas.2304619121